Canada markets open in 1 hour 54 minutes

Corbus Pharmaceuticals Holdings, Inc. (CRBP)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
41.62-2.06 (-4.72%)
At close: 04:00PM EDT
40.79 -0.83 (-1.99%)
After hours: 07:40PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close43.68
Open43.13
Bid37.69 x 4000
Ask37.70 x 800
Day's Range39.01 - 43.13
52 Week Range3.03 - 49.87
Volume236,403
Avg. Volume935,481
Market Cap436.723M
Beta (5Y Monthly)2.43
PE Ratio (TTM)N/A
EPS (TTM)-10.31
Earnings DateMay 07, 2024 - May 13, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est55.00
  • GlobeNewswire

    Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

    Encouraging CRB-701 (SYS6002) First-in-Human Data Presented at ASCO-GU 2024; first patient expected to be dosed in US Ph1 study by end of March 2024 IND Application for CRB-601 cleared; Ph1 study on track to commence in Summer of 2024Pre-clinical data for CRB-913 presented at Obesity Week; IND filing on track by the end of 2024$127M of cash & investments at February 2, 2024; 3+ years of projected runway through Q1 2027Appointed Dr. Dominic Smethurst as Chief Medical Officer NORWOOD, Mass., March

  • GlobeNewswire

    Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit

    NORWOOD, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a panel discussion at BMO Capital Markets Inaugural BMO Obesity Summit to be held on March 20, 2024 in New York City, NY. Details of the panel discussion are as follow: BMO Capital Markets Inaugural Obesity SummitPanel Title: Emerging Therapeutics LandscapeDate: Wednesda

  • GlobeNewswire

    Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer

    NORWOOD, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today announced the appointment of Dr. Dominic Smethurst, MA MRCP, as the Company’s Chief Medical Officer (CMO). In this role, Dr. Smethurst will lead the clinical development of the Company’s investigational oncology drugs: CRB-701, a next generation Nectin-4 targeting antibody drug conjugate (ADC) develope